The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), had caused over 382 million cases and over 2.7 million deaths globally as of 23 March 2021. By that date, at least 10 SARS-CoV-2 variants had emerged. The transmissibility and lethality of the variants are higher than those of the Wuhan reference strain. Therefore, a universal vaccine for the reference strain and all variants (present and future) is indispensable. The coronavirus envelope (E) protein is an integral membrane protein crucial to the viral lifecycle and the pathogenesis of coronaviruses. The SARS-CoV-2 E protein has a postsynaptic density protein 95/Drosophila disc large tumor suppressor/zonula occludens-1 (PDZ) binding motif (PBM), and its interaction with PDZ-domain-2 of the human tight junction protein may interrupt the integrity of lung epithelium. Furthermore, the SARS-CoV-2 E protein itself is a homopentameric cation channel viroporin, which may be involved in viral release. This protein is thus a potential target for the development of a universal COVID-19 vaccine, because of its highly conserved amino acid sequence. The variant mutations occur mainly in the spike protein, and conservation of E protein remained in most Variants of Concern (VOC). Only one of the extant VOC have mutations in the E protein that P71L mutation occurs in the South African variant 501Y.V2 (B.1.351). If a vaccine is designed to target E protein, two scenarios are possible: 1) SARS-CoV-2 maintains a highly conserved E protein amino acid sequence, rendering the virus consistently or permanently susceptible to the vaccine; or 2) the E protein mutates and new variants evolve accordingly. In scenario 2, the tertiary structure and function of the E protein homopentameric cation channel viroporin, PBM, or other aspects affecting pathogenicity would be attenuated. Either scenario would thus ameliorate the pandemic. I therefore propose that a vaccine targeting the SARS-CoV-2 E protein would be effective against the Wuhan reference strain and all current and future SARS-CoV-2 variants. Efforts to create E protein-based vaccines are ongoing. Further research and clinical trials are needed to realize this universal COVID-19 vaccine.
References
[1]
Johns Hopkins University (2021) COVID-19 Dashboard. Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU), Baltimore. https://coronavirus.jhu.edu/map.html
[2]
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. (2020) Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. Lancet, 395, 497-506. https://doi.org/10.1016/S0140-6736(20)30183-5
[3]
Challen, R., Brooks-Pollock, E., Read, J.M., Dyson, L., Tsaneva-Atanasova, K., et al. (2021) Risk of Mortality in Patients Infected with SARS-CoV-2 Variant of Concern 202012/1: Matched Cohort Study. BMJ, 372, n579. https://doi.org/10.1136/bmj.n579
[4]
Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., et al. (2021) Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca Vaccines on Covid-19 Related Symptoms, Hospital Admissions, and Mortality in Older Adults in England: Test Negative Case-Control study. BMJ, 373, n1088. https://doi.org/10.1136/bmj.n1088
[5]
Sheridan, C. (2021) Innovators Target Vaccines for Variants and Shortages in Global South. Nature Biotechnology, 39, 393-396. https://doi.org/10.1038/d41587-021-00001-x
[6]
Chan, J.F., Kok, K.H., Zhu, Z., Chu, H., To, K.K., et al. (2020) Genomic Characterization of the 2019 Novel Human-Pathogenic Coronavirus Isolated from a Patient with Atypical Pneumonia after Visiting Wuhan. Emerging Microbes & Infections, 9, 221-236. https://doi.org/10.1080/22221751.2020.1719902
[7]
Hu, D. (2018) Bat SARS-Like Coronavirus Isolate Bat-SL-CoVZXC21, Complete Genome. GeneBank. https://www.ncbi.nlm.nih.gov/nuccore/MG772934
[8]
Hu, D. (2018) Bat SARS-Like Coronavirus Isolate Bat-SL-CoVZC45, Complete Genome. GenBank. https://www.ncbi.nlm.nih.gov/nuccore/MG772933.1
[9]
Hu, D., Zhu, C., Ai, L., He, T., Wang, Y., Ye, F., et al. (2018) Genomic Characterization and Infectivity of a Novel SARS-Like Coronavirus in Chinese Bats. Emerging Microbes & Infections, 7, Article No. 154. https://doi.org/10.1038/s41426-018-0155-5
[10]
Yan, L.M., Kang, S., Guan, J. and Hu, S. (2020) Unusual Features of the SARS-CoV-2 Genome Suggesting Sophisticated Laboratory Modification Rather Than Natural Evolution and Delineation of Its Probable Synthetic Route. Zenodo. http://doi.org/10.5281/zenodo.4028830
[11]
Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., et al. (2020) A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin. Nature, 579, 270-273. https://doi.org/10.1038/s41586-020-2012-7
[12]
Yan, L.M., Kang, S., Guan, J. and Hu, S. (2020) SARS-CoV-2 Is an Unrestricted Bioweapon: A Truth Revealed through Uncovering a Large-Scale, Organized Scientific Fraud. Zenodo.
[13]
Schoeman, D. and Fielding, B.C. (2019) Coronavirus Envelope Protein: Current Knowledge. Virology Journal, 16, Article No. 69. https://doi.org/10.1186/s12985-019-1182-0
[14]
DeDiego, M.L., Alvarez, E., Almazán, F., Rejas, M.T., Lamirande, E., Roberts, A., et al. (2007) A Severe Acute Respiratory Syndrome Coronavirus That Lacks the E Gene Is Attenuated in Vitro and in Vivo. Journal of Virology, 81, 1701-1713. https://doi.org/10.1128/JVI.01467-06
[15]
Teoh, K.T., Siu, Y.L., Chan, W.L., Schluter, M.A., Liu, C.J., et al. (2010) The SARS Coronavirus E Protein Interacts with PALS1 and Alters Tight Junction Formation and Epithelial Morphogenesis. Molecular Biology of the Cell, 21, 3838-3552. https://doi.org/10.1091/mbc.e10-04-0338
[16]
Shepley-McTaggart, A., Sagum, C.A., Oliva, I., Rybakovsky, E., DiGuilio, K., et al. (2020) SARS-CoV-2 Envelope (E) Protein Interacts with PDZ-Domain-2 of Host Tight Junction Protein ZO1. bioRxiv. https://doi.org/10.1101/2020.12.22.422708
[17]
Westerbeck, J.W. and C.E. Machamer (2019) The Infectious Bronchitis Coronavirus Envelope Protein Alters Golgi pH To Protect the Spike Protein and Promote the Release of Infectious Virus. Journal of Virology, 93, e00015-19. https://doi.org/10.1128/JVI.00015-19
[18]
Tomar, P.P.S. and I.T. Arkin (2020) SARS-CoV-2 E Protein Is a Potential Ion Channel That Can Be Inhibited by Gliclazide and Memantine. Biochemical and Biophysical Research Communications, 530, 10-14. https://doi.org/10.1016/j.bbrc.2020.05.206
[19]
Saurabh, K., Solovchuk, M. and Sheu, T.W. (2020) Investigating Ion Transport Inside the Pentameric Ion Channel Encoded in COVID-19 E Protein. Physical Review E, 102, Article ID: 052408. https://doi.org/10.1103/PhysRevE.102.052408
[20]
Mandala, V.S., M.J. McKay, A.A. Shcherbakov, A.J. Dregni, A. Kolocouris, et al. (2020) Structure and Drug Binding of the SARS-CoV-2 Envelope Protein Transmembrane Domain in Lipid Bilayers. Nature Structural & Molecular Biology, 27, 1202-1208. https://doi.org/10.1038/s41594-020-00536-8
[21]
Cabrera-Garcia, D., Bekdash, R., Abbott, G.W., Yazawa, M. and Harrison, N.L. (2021) The Envelope Protein of SARS-CoV-2 Increases Intra-Golgi pH and Forms a Cation Channel That Is Regulated by pH. The Journal of Physiology, 599, 2851-2868. https://doi.org/10.1113/JP281601
[22]
Rahman, M.S., Hoque, M.N., Islam, M.R., Islam, I., Mishu, I.D., Rahaman, M.M., et al. (2020) Mutational Insights into the Envelope Protein of SARS-CoV-2. Gene Reports, 1, Article ID: 2020080665. https://doi.org/10.20944/preprints202008.0665.v1
[23]
Rambaut, A., Loman, N., Pybus, O., Barclay, W., Barrett, J., et al. (2021) Preliminary Genomic Characterisation of an Emergent SARS-CoV-2 Lineage in the UK Defined by a Novel Set of Spike Mutations. Virological. https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563
[24]
Africa Centres for Disease Control and Prevention (2020) Alert Notification: New SARS-CoV-2 Variant with Multiple Spike Protein Mutations. Africa Centres for Disease Control and Prevention, Addis Ababa. https://africacdc.org/download/alert-notification-new-sars-cov-2-variant-with-multiple-spike-protein-mutations/
[25]
Singh, J., Samal, J., Kumar, V., Sharma, J., Agrawal, U., et al. (2021) Structure-Function Analyses of New SARS-CoV-2 Variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications. Viruses, 13, Article No. 439. https://doi.org/10.3390/v13030439
[26]
Bhattacharya, S., Banerjee, A. and Ray, S. (2021) Development of New Vaccine Target against SARS-CoV2 Using Envelope (E) Protein: An Evolutionary, Molecular Modeling and Docking Based Study. International Journal of Biological Macromolecules, 172, 74-81. https://doi.org/10.1016/j.ijbiomac.2020.12.192
[27]
Ghafouri, F., Cohan, R.A., Noorbakhsh, F., Samimi, H. and Haghpanah, V. (2020) An In-Silico Approach to Develop of a Multi-Epitope Vaccine Candidate against SARS-CoV-2 Envelope (E) Protein. Research Square. [Preprint]. https://doi.org/10.21203/rs.3.rs-30374/v1
[28]
Jakhar, R. and Gakhar, S.K. (2020) An Immunoinformatics Study to Predict Epitopes in the Envelope Protein of SARS-CoV-2. Canadian Journal of Infectious Diseases and Medical Microbiology, 2020, Article ID: 7079356. https://doi.org/10.1155/2020/7079356
[29]
Abdelmageed, M.I., Abdelmoneim, A.H., Mustafa, M.I., Elfadol, N.M., Murshed, N.S., et al. (2020) Design of a Multiepitope-Based Peptide Vaccine against the E Protein of Human COVID-19: An Immunoinformatics Approach. Biomed Res Int, 2020, Article ID: 2683286. https://doi.org/10.1155/2020/2683286
[30]
Teijaro, J.R. and Farber, D.L. (2021) COVID-19 Vaccines: Modes of Immune Activation and Future Challenges. Nature Reviews Immunology, 21, 195-197. https://doi.org/10.1038/s41577-021-00526-x
[31]
Sarkar, M. and Saha, S. (2020) Structural Insight into the Role of Novel SARS-CoV-2 E Protein: A Potential Target for Vaccine Development and Other Therapeutic Strategies. PLoS ONE, 15, e0237300. https://doi.org/10.1371/journal.pone.0237300